Opening The Black Box: Moving To Explainable AI

By Munshi Imran Hossain, Senior Analyst, Cytel

Nowadays, it’s difficult to pick up a mainstream newspaper or read an industry publication without seeing reference to Artificial Intelligence or AI and progress towards innovations like autonomous vehicles, or customer behavior prediction. For the biopharma industries specifically, AI represents an opportunity to avert the R&D productivity crisis with paradigm-shifting applications such as in-silico drug design, prediction of trial risks and big data analytics.

However, with every opportunity, there are risks and challenges, and in this blog, I will discuss how pharma needs to address the opacity of AI to ensure trust and credibility with all stakeholders.